Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
4
×
life sciences
national blog main
national top stories
roche
4
×
san francisco blog main
san francisco top stories
biotech
boston blog main
boston top stories
clinical trials
merck
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
adverum biotechnologies
biogen
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
deals
detroit blog main
detroit top stories
diagnostics
gene therapy
glaxosmithkline
ifm therapeutics
immunotherapy
indiana blog main
What
drug
4
×
bio
roundup
cancer
patients
pricing
acquisitions
advanced
advantages
albert
arrival
award
bar
biggest
bourla
brings
ceo
company
crispr
data
death
decades
dems
despite
expect
family
future
gamble
given
hardest
hit
hottest
hunters
immunotherapy
imports
ipo
longer
lung
maker
maps
Language
unset
unknown
Current search:
amgen
×
roche
×
drug
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
